Prostate-specific membrane antigen (PSMA) is overexpressed in more than 80% of prostate cancer tumors, making it a promising diagnostic and...

ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer

The Video Journal of Oncology (VJOncology) podcast covers the latest oncology news from international experts across a view variety of solid tumors. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjoncology.com

Share ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer

Sign up to save your podcasts

ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer

ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer